Dendropharm

Nanotechnology for Potent Painkillers Without Addiction or Sedation

1/1 Photos

Key project data

Target amount

1,0M EUR

Valuations

10,0M EUR

Potentiële rendementen

6.8-8.16x

Would AI invest?

51/100

100

Investeer nu

Door AI gegenereerd overzicht

This overview is generated using artificial intelligence based on information available on the platform’s project page and publicly accessible data. It is provided for informational purposes only and does not constitute investment advice, financial guidance, risk assessment, or project scoring. Platforms and project owners are not involved in the creation, review, or endorsement of this content.

AI project overview

Condensed summary based on project data

<h1><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>DendroPharm GmbH — Crowdfunding Investor Memo</span></span></h1>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><em>Nanotechnology for potent painkillers without addiction or sedation.</em></span></span></p>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong>Sector: </strong>Pharma / nanotech drug delivery (deeptech, regulated)   ·   <strong>Stage: </strong>Pre-clinical (Phase I planned Q3 2026)   ·   <strong>HQ: </strong>Berlin, Germany   ·   <strong>Raise: </strong>EUR 100k threshold – EUR 1.0m maximum</span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:200px">
<p> </p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Why this score:</span></strong></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p style="text-align:center"><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">AI SCORE</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">The headline 48–52% annual return is a company projection on a profit-/exit-linked loan, not a fixed coupon; the VIB states neither principal nor interest is assured under negative development.</span></span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p style="text-align:center"><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="font-size:28.0pt"><span style="color:black">51 / 100</span></span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">The investment is a deeply subordinated loan with a pre-insolvency enforcement bar: payments can be lawfully blocked before insolvency and the lender is paid only after all other creditors.</span></span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p style="text-align:center"><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style='font-family:"Segoe UI Emoji",sans-serif'><span style="color:black">⚠️</span></span><span style="color:black"> Caution</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">The asset is pre-clinical (Phase I planned Q3 2026) and the return path depends on out-licensing modelled for 2028–2031 plus a not-yet-secured EUR 3–6m VC round for Phase II.</span></span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p style="text-align:center"> </p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">The two financial scenarios disagree on 2025 ‘actuals’ and on out-licensing magnitude/timing (EUR 45m vs 35m in 2030).</span></span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p style="text-align:center"> </p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Credible foundations: ISO 9001 (2015), GMP (2022, LaGeSo), manufacturing-authorisation inspection completed Sept 2025, BMBF/Pro FIT grants, and a 12-person specialist team.</span></span></span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<p> </p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#e6f1fb; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:624px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">ℹ️ <strong>This is not investment advice.</strong> </span><span style="color:#000000">The purpose of this overview is to help potential investors preselect crowdfunding projects quickly without making a final investment decision.  Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform. AI can make mistakes, so you need to double-check data.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>🏢 Company description</span></span></h2>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>DendroPharm GmbH (Berlin; HRB 151543 B) is a pharmaceutical R&amp;D and contract-manufacturing company developing a nano-carrier platform branded “NanoPain™” / “NanoOpiate.” The company reports the carrier is too large to cross the blood-brain barrier, so it delivers an already-approved opioid to inflamed or post-operative tissue rather than the brain, aiming to relieve pain without the addiction and respiratory-depression risks of conventional opioids; the intravenous candidate is “DENA-19.” Founded in 2013 as a spin-off from Freie Universität Berlin (the project team reports it “took over the project in 2017”), it is led by founder/CEO Dr. Sam Dylan Moré, who holds 56.39% of the equity. The company reports a 12-person specialist team across more than 650 sqm including 300 sqm of cleanrooms and 5 analytical laboratories, ISO 9001 certification since 2015, GMP certification in 2022 (LaGeSo), and a completed manufacturing-authorisation inspection in September 2025. Current revenue is project/CDMO-based (the company reports ~EUR 600,000 of 2026 customer inquiries) alongside a veterinary cat-ointment out-licensed in 2021 and expected to be approved in 2026. This round — a profit-participating subordinated loan with an EUR 100,000 threshold and EUR 1,000,000 maximum — is earmarked to fund the first human clinical trial (Phase I) and to advance out-licensing of the Nano-Pain technology. The company separately plans a EUR 3–6m venture-capital equity round to enable Phase II in 2027.</span></span></p>
<h2><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>🎯 <span style="color:#000000">Potential returns</span></span></span></h2>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<thead>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:113px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Target return</span></strong></span></span></p>
</td>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:113px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Time horizon</span></strong></span></span></p>
</td>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:224px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Target basis</span></strong></span></span></p>
</td>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:173px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">AI view on reaching this goal</span></strong></span></span></p>
</td>
</tr>
</thead>
<tbody>
<tr>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:113px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">🎯 6.80–8.16x</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:113px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">⏱ ~5 yrs (to 30.04.2031)</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:224px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Company-provided</span></strong><span style="color:black"> — the company states 48% (base) to 52% (target) IRR per year over a 5-year period, i.e. 6.80x–8.16x.</span></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:173px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Plausible only on a successful out-licensing exit; under the VIB’s neutral/negative cases the multiple is not achieved and capital loss is possible.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>📈 Path to target return</span></span></h2>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:173px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Company methodology</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:451px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Returns are success-based, not contractual. During the term the investor earns an annual ‘success interest’ equal to their participation quota × the company’s prior-year net profit; at the end of term a ‘bonus interest’ based on company value (or, absent a recent financing round, 100% of last-year revenue); and, on a sale of &gt;50% of shares/assets, an ‘exit interest’ (a pro-rata share of net proceeds) plus principal back. The 48–52% IRR / 6.8–8.16x figures are the company’s modelled outputs assuming positive growth and a successful out-licensing exit.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:173px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Comparable exits cited</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:451px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Not disclosed in provided materials. The company estimates lifetime out-licensing revenue of EUR 1.2–1.8bn over the patent term (company-stated, unverified), with 20–30% within the first four years.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:173px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Milestones expected</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:451px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Phase I start — Q3 2026</span></span></span></li>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Phase II start (patient efficacy) — Q3 2027 (requires a EUR 3–6m VC round)</span></span></span></li>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Depot-formulation Phase II — 2029</span></span></span></li>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Out-licensing — 2028–2031</span></span></span></li>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Veterinary cat-ointment approval — 2026</span></span></span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>💶 Valuation</span></span></h2>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:200px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Pre-money valuation</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">EUR 10.0m (set by the issuer, before the campaign).</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Post-money valuation</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">EUR 11.0m implied at the EUR 1.0m maximum raise (derived).</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Instrument</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Partiarisches Nachrangdarlehen — a profit-participating subordinated loan. This is NOT equity: the investor receives no shares and no ownership.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">How the valuation was set</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Methodology not disclosed in provided materials — the EUR 10m figure is stated as issuer-determined, with no DCF or comparables basis provided.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">External benchmarks</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">Insufficient comparables for this sector and stage; no third-party valuation was found in public sources. The asset is pre-Phase-I, so the figure is forward-looking on out-licensing potential.</span></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Notable terms</span></strong></span></span></p>
</td>
<td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">A ~10% valuation bonus applies to investors within 31 days of public presentation (EUR 100 → 0.001000% participation quota vs 0.000909% standard). Issuer-borne costs total 15% of amounts raised (FunderNation 6%, pooling ~6%, marketing up to 3%).</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>📜 Instrument &amp; investor terms</span></span></h2>
<h3><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>What you own</span></span></h3>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>You own a profit-participating subordinated loan (German: partiarisches Nachrangdarlehen), not shares. There is no share class because this is debt, not equity — you become a lender to the company, not a co-owner, and you do not appear on the company’s cap table. The loan is made directly to DendroPharm (not through a nominee or SPV), but a separate pooling agreement via FunderNation Support UG provides a collective coordination procedure (for example, to negotiate a whole-loan buy-…</span></span></p>

See full overview

Ask question

Ask AI about this project

Beta